JP2003525251A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003525251A5 JP2003525251A5 JP2001563137A JP2001563137A JP2003525251A5 JP 2003525251 A5 JP2003525251 A5 JP 2003525251A5 JP 2001563137 A JP2001563137 A JP 2001563137A JP 2001563137 A JP2001563137 A JP 2001563137A JP 2003525251 A5 JP2003525251 A5 JP 2003525251A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- polypeptide
- zcyto7
- expression
- schwann cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 description 14
- 102000013691 Interleukin-17 Human genes 0.000 description 5
- 108050003558 Interleukin-17 family Proteins 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 208000004275 Demyelinating Disease Diseases 0.000 description 4
- 101700044982 IL17B Proteins 0.000 description 4
- 210000001428 Peripheral Nervous System Anatomy 0.000 description 4
- 210000004116 Schwann Cells Anatomy 0.000 description 2
- 230000003210 demyelinating Effects 0.000 description 2
- 230000001737 promoting Effects 0.000 description 2
- 208000001636 Diabetic Neuropathy Diseases 0.000 description 1
- 206010012680 Diabetic neuropathy Diseases 0.000 description 1
- 208000002183 Guillain-Barre Syndrome Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000015528 Myelin Basic Protein Human genes 0.000 description 1
- 108010025255 Myelin Basic Protein Proteins 0.000 description 1
- 102000006297 Myelin P0 Protein Human genes 0.000 description 1
- 108010058495 Myelin P0 Protein Proteins 0.000 description 1
- 206010029331 Neuropathy peripheral Diseases 0.000 description 1
- 208000006473 Polyradiculopathy Diseases 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000003612 virological Effects 0.000 description 1
Description
【特許請求の範囲】
【請求項１】 シュワン細胞におけるミエリンの発現を促進するための医薬組成物であって、Zcyto7ポリペプチドを含んで成る医薬組成物。
【請求項２】 Zcyto7ポリペプチドが配列番号２，７，及び９〜２８から成る群から選択される、請求項１に記載の医薬組成物。
【請求項３】 末梢神経系（ＰＮＳ）の脱髄性疾患を処置するための医薬組成物であって、Zcyto7を含んで成る医薬組成物。
【請求項４】 脱髄性疾患が、糖尿病性神経障害、ギラン・バレー症候群、慢性脱髄性疾患、急性脱髄性多発神経根筋障害及びヒト免疫不全性ウイルス性脱髄性神経障害から成る群から選択される、請求項３に記載の医薬組成物。
【請求項５】 シュワン細胞におけるミエリンの発現を促進するための医薬組成物であって、インターロイキン−１７(IL-17)ポリペプチドを含んで成る医薬組成物。
【請求項６】 末梢神経系（ＰＮＳ）の脱髄性疾患を処置するための医薬組成物であって、インターロイキン−１７(IL-17)ポリペプチドをを含んで成る医薬組成物。
【請求項７】 シュワン細胞によるＰ０タンパク質の発現を促進するための医薬組成物であって、Zcyto7ポリペプチド又はIL-17を含んで成る医薬組成物。
【請求項８】 シュワン細胞によるミエリン塩基性タンパク質の発現を促進するための医薬組成物であって、Zcyto7ポリペプチド又はIL-17を含んで成る医薬組成物。
[Claims]
(1) In Schwann cellsTo promote myelin expressionPharmaceutical compositionWherein the Zcyto7 polypeptide isPharmaceutical composition comprising.
2. The method of claim 1, wherein the Zcyto7 polypeptide is selected from the group consisting of SEQ ID NOs: 2, 7, and 9-28.Pharmaceutical composition.
3. A method for treating a demyelinating disease of the peripheral nervous system (PNS).Pharmaceutical compositionAndZcyto7ComprisePharmaceutical composition.
4. The demyelinating disease comprises diabetic neuropathy, Guillain-Barre syndrome, chronic demyelinating disease, acute demyelinating polyradiculopathy and human immunodeficiency viral demyelinating neuropathy. 4. The method of claim 3, wherein the group is selected from a group.Pharmaceutical composition.
(5) In Schwann cellsTo promote myelin expressionPharmaceutical compositionWherein the interleukin-17 (IL-17) polypeptide isPharmaceutical composition comprising.
6. A method for treating a demyelinating disease of the peripheral nervous system (PNS).Pharmaceutical compositionAndInterleukin-17 (IL-17) polypeptideComprisingPharmaceutical composition.
7. A method for promoting the expression of a P0 protein by Schwann cells.Pharmaceutical compositionComprising a Zcyto7 polypeptide or IL-17.Pharmaceutical composition comprising.
8. A method for promoting the expression of myelin basic protein by Schwann cells.Pharmaceutical compositionComprising a Zcyto7 polypeptide or IL-17.Pharmaceutical composition comprising.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51522300A | 2000-02-29 | 2000-02-29 | |
| US09/515,223 | 2000-02-29 | ||
| PCT/US2001/006294 WO2001064240A2 (en) | 2000-02-29 | 2001-02-27 | Methods for promoting production of myelin by schwann cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003525251A JP2003525251A (en) | 2003-08-26 |
| JP2003525251A5 true JP2003525251A5 (en) | 2008-04-17 |
Family
ID=24050447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001563137A Pending JP2003525251A (en) | 2000-02-29 | 2001-02-27 | Method for promoting myelin production by Schwann cells |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1259253A2 (en) |
| JP (1) | JP2003525251A (en) |
| AU (1) | AU2001241816A1 (en) |
| CA (1) | CA2401716A1 (en) |
| WO (1) | WO2001064240A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1379278A4 (en) * | 2001-03-26 | 2004-08-11 | Zymogenetics Inc | Method of inducing proliferation of retinal stem cells |
| JP2010509364A (en) * | 2006-11-08 | 2010-03-25 | ザイモジェネティクス， インコーポレイテッド | IL-17B for use in wound healing |
| AU2015314685B2 (en) * | 2014-09-12 | 2021-02-25 | The Administrators Of The Tulane Educational Fund | Neural microphysiological systems and methods of using the same |
| CA3023451A1 (en) | 2016-05-06 | 2017-11-09 | Exicure, Inc. | Liposomal spherical nucleic acid (sna) constructs presenting antisense oligonucleotides (aso) for specific knockdown of interleukin 17 receptor mrna |
| WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000073452A2 (en) * | 1999-06-02 | 2000-12-07 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US5707829A (en) * | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
| EP0839196B1 (en) * | 1995-07-19 | 2005-05-11 | Genetics Institute, LLC | Human ctla-8 and uses of ctla-8-related proteins |
| CA2288360A1 (en) * | 1997-04-25 | 1998-11-05 | Zymogenetics, Inc. | Mammalian cytokine-like factor 7 |
| WO1999003982A1 (en) * | 1997-07-16 | 1999-01-28 | Human Genome Sciences, Inc. | Interleukin-20 |
| ES2380812T3 (en) * | 1999-12-23 | 2012-05-18 | Genentech, Inc. | IL-17 homologous polypeptides and therapeutic uses thereof |
-
2001
- 2001-02-27 EP EP01913120A patent/EP1259253A2/en not_active Withdrawn
- 2001-02-27 WO PCT/US2001/006294 patent/WO2001064240A2/en active Application Filing
- 2001-02-27 AU AU2001241816A patent/AU2001241816A1/en not_active Abandoned
- 2001-02-27 CA CA002401716A patent/CA2401716A1/en not_active Abandoned
- 2001-02-27 JP JP2001563137A patent/JP2003525251A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001514858A5 (en) | ||
| JP2004511201A5 (en) | ||
| JP2003522514A5 (en) | ||
| JP2003500040A5 (en) | ||
| PT1626985E (en) | Generation of artificial binding proteins based on ubiquitin proteins | |
| JP2002513556A5 (en) | ||
| JP2005509609A5 (en) | ||
| JP2008505985A5 (en) | ||
| JP2003527079A5 (en) | ||
| NZ601544A (en) | Combination therapy for the treatment of ocular neovascular disorders | |
| JP2004501101A5 (en) | ||
| RU2000124084A (en) | Chimeric antibody that binds to human CD40 (variants), nucleic acid molecule (variants), expression vector (variants), humanized antibody (variants), pharmaceutical composition for treating a T-cell mediated disease (variants), method for treating a patient for a disease mediated by T cells (options) | |
| JP2002527052A5 (en) | ||
| WO1995021919A3 (en) | Protein having tpo activity | |
| JP2009520758A5 (en) | ||
| JP2008503217A5 (en) | ||
| JP2002542827A5 (en) | ||
| DK1969003T3 (en) | Applications of a neurotrophic factor protein | |
| JP2005506275A5 (en) | ||
| JP2003504062A5 (en) | ||
| JP2001526242A5 (en) | ||
| JP2003525251A5 (en) | ||
| RU2005123050A (en) | SUPER ANTIGENIC FUSION PROTEINS AND THEIR USE | |
| JP2002522512A5 (en) | ||
| RU2007106900A (en) | IMMUNOGENIC COMPLEXES, METHOD FOR THEIR PREPARATION AND THEIR APPLICATION IN PHARMACEUTICAL COMPOSITIONS |